Indonesia antirheumatic drugs market was valued at US$3,543.837 million in 2020. The market is projected to grow at a CAGR of 3.00% to attain a value of US$4,359.458 million by 2027.
The market for antirheumatic drugs in Indonesia is projected to witness a healthy CAGR throughout the forecast period, primarily on account of the high incidence of malaria throughout the country, along with the moderate prevalence of numerous rheumatic diseases, such as osteoarthritis and rheumatoid arthritis, among others. According to the World Health Organization, the prevalence of osteoarthritis at the age of 61 in Indonesia was around 5% in 2015. Furthermore, the exponential growth of the geriatric population of the country is also bolstering the growing demand for numerous types of antirheumatic drugs throughout the country, thus positively impacting the market growth during the next five years. For instance, the population aged 65 and above in the country reached 15,677,491 by 2018 from 11,661,484 in 2008 (Source: The World Bank Group).
Furthermore, malaria is considered a serious health problem in the country. Socio-demographic factors are considered to be highly responsible for the high impact of malaria throughout the country. Also, according to the data from the World Health Organization, in 2017, the reported confirmed malaria cases in health facilities across the country were around 261,617. Also, the division of the population based on high transmission (>1 case per 1000 population) was around 16.9 million, and low transmission (>1 case per 1000 population) was evaluated at around 247.1 million for the same period. Therefore, the high prevalence of malaria in Indonesia is also projected to be one of the key factors supplementing the antirheumatic drugs market growth in the country over the next five years.
Indonesia's antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Indonesian antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).
Product Offerings by the market players in the Indonesian antirheumatic drugs market:
COVID-19 had a significant impact on the Indonesian antirheumatic drugs market. The growing prevalence of rheumatic patients led to the increased demand for drugs in the country. Nevertheless, the enforcement of the lockdown and social distancing measures by the Indonesian government led to the closure of many production facilities and low staffing, reducing productivity. The travel restrictions also affected the imports and exports in Indonesia, creating a gap in the supply and demand chain. The aforementioned factors slowed down the market's growth.
1.1. Market Overview
1.2. COVID-19 Impact
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Indonesia Antirheumatic Drug Market Analysis, By Type of Disease
5.3. Rheumatoid Arthritis
6. Indonesia Antirheumatic Drug Market Analysis, By Type of Molecule
7. Indonesia Antirheumatic Drug Market Analysis, By Sales Channel
7.3. Over-The-Counter (OTC)
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Pfizer Inc.
9.2. GlaxoSmithKline plc
9.3. F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.